author-photo

A. W. S. Ritchie

36

Papers

728

Citations

Citation Trend

Filter By

Papers (29) Sort By

Journal Conference Others

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (114)
The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer

2019 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (1)
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (114)
LBA4Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (22)
LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Response to ‘High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice’, by Tanguay et al.

2016 Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476)

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (12)
Docetaxel (Doc) plus /- zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476)

2015
Show All
- Source
- Cite
- Save
Citations (7)